Key result
Alteplase yields ~69% 90-day good functional recovery in ischemic stroke with low symptomatic hemorrhage.
Why the study?
The safety and effectiveness of thrombolytic therapy with Revelisa (alteplase) in patients with ischemic stroke in real clinical practice required evaluation.
What is the real-world safety and effectiveness of intravenous thrombolytic therapy with alteplase (Revelisa) administered within 4.5 hours in patients with acute ischemic stroke?
Cohort (n=550)
Open-label
Yes
What is the real-world safety and effectiveness of intravenous thrombolytic therapy with alteplase (Revelisa) administered within 4.5 hours in patients with acute ischemic stroke?
Answers are grounded in this paper and cite their sources.
Real-world registry data demonstrate that intravenous alteplase (Revelisa) for acute ischemic stroke yields significant neurological improvement and a 68.5% rate of good functional recovery at 90 days with an acceptable safety profile (2.3% symptomatic intracranial hemorrhage).
Objective Evaluation of the safety and effectiveness of thrombolytic therapy (TLT) with the drug Revelisa (alteplase) in patients with ischemic stroke (AI) in real clinical practice. Material and methods An open prospective multicenter non-interventional register study was conducted, which included 550 patients with AI - 259 (47.1%) women and 291 (52.9%) men; average age 67.7±12.6 years. All included patients underwent TLT with the drug Revelisa within 4.5 hours from the onset of the disease and, according to the protocol of reperfusion therapy of AI, clinical, instrumental and laboratory examinations were performed. Symptomatic hemorrhagic transformation (GT) was determined in accordance with the criteria of the ECASS 3 study. Results The majority of patients (95.8%) suffered from hypertension, 69.6% had chronic heart failure, 53.8% had coronary heart disease, 38.7% had various cardiac arrhythmias, 20.7% of patients suffered from type 2 diabetes mellitus. A day after TLT, an improvement of 4 points or more on the NIHSS scale was noted in 45% of patients. The average dynamics index on the NIHSS stroke scale after a day was -3.2±4.7 and -4.4±6.1 per 7 females (p<0.0001). GT of the lesion of the brain developed in 10.9% of cases, symptomatic GT was diagnosed in 12 (2.3%) patients. The hospital mortality rate was 12.7%. The proportion of patients with good functional recovery (0-2 points on the modified Rankin scale (mRS)) at discharge, on days 30 and 90 was 44.7%, 59.2% and 68.5%, respectively. Conclusion Performing TLT with the drug Revelisa in patients with AI leads to a statistically significant regression of neurological symptoms. A significant proportion of patients achieve a favorable clinical outcome upon discharge from the hospital and in the long term. The obtained data on the efficacy and safety profile correlate with previously published register studies of alteplase in AI.
No takes yet. Share an insight, caveat, or question.
Солдатов et al. (2022) conducted a cohort in Ischemic stroke (n=550). Alteplase (Revelisa) intravenous thrombolytic therapy was evaluated on Good functional recovery (0-2 points on the modified Rankin scale [mRS]) at 90 days. Intravenous alteplase (Revelisa) within 4.5h of ischemic stroke achieved good 90-day functional recovery (mRS 0-2) in 68.5% of patients, with 2.3% symptomatic hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: